Gordon Fox • October 7, 2021
Consequences of obesity for health in HCM patients

Weight management can make a big difference for HCM patients. That’s not just something cardiologists say to lecture you.

A 2020 paper, Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy , provides some insight. This study by a group of leading HCM researchers from three countries examines the health consequences of body weight in nearly 3300 HCM patients.

The scientists used the SHARE (Sarcomeric Human Cardiomyopathy Registry), a database relating patient genetic test results to their health. SHARE was established by eight HCM centers (in Brazil, Italy, Netherlands, and the USA).

The results are clear. Those with a body mass index (BMI) greater than 30 developed afib at about 1.4 times the rate of those with “normal” BMI. They were about 1.9 times more likely to develop heart failure. These patterns hold true even after the researchers controlled for age, sex, obstruction, and genotype.

Carrying too much weight puts us at risk of serious heart problems. This is a powerful reason to start a weight loss program!

Source: JAMA Cardiol. 2020;5(1):65-72. doi:10.1001/jamacardio.2019.4268

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts